{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:41:46Z","timestamp":1767706906549,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["FI20\/00090","ICI20\/00131"],"award-info":[{"award-number":["FI20\/00090","ICI20\/00131"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.biopha.2021.112083","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T18:09:27Z","timestamp":1629828567000},"page":"112083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["ABCB1 C3435T, G2677T\/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics"],"prefix":"10.1016","volume":"142","author":[{"given":"Pablo","family":"Zubiaur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"del Peso-Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Enrique-Benedito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Mej\u00eda-Abril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Navares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Villapalos-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Carmen","family":"Ovejero-Benito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112083_bib1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.biopha.2021.112083_bib2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1684\/epd.2019.1083","article-title":"Antiepileptic drugs: evolution of our knowledge and changes in drug trials","volume":"21","author":"Perucca","year":"2019","journal-title":"Epileptic Disord. Int. Epilepsy J. Videotape"},{"key":"10.1016\/j.biopha.2021.112083_bib3","first-page":"471","article-title":"Pharmacogenetics and antiepileptic drug metabolism: implication of genetic variants in cytochromes P450","volume":"56","author":"Salda\u00f1a-Cruz","year":"2013","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.biopha.2021.112083_bib4","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cpt.1004","article-title":"Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update","volume":"103","author":"Phillips","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2021.112083_bib5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1756285615589711","article-title":"A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures","volume":"8","author":"Rocamora","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.biopha.2021.112083_bib6","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.biopha.2021.112083_bib7","unstructured":"European Medicines Agency, Zebinix-EMA drug label-product-information., (n.d.). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zebinix-epar-product-information_en.pdf (Accessed 19 July 2021)."},{"key":"10.1016\/j.biopha.2021.112083_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4137\/JCNSD.S4888","article-title":"A Review of Eslicarbazepine Acetate for the Adjunctive Treatment of Partial-Onset Epilepsy","volume":"3","author":"Singh","year":"2011","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.biopha.2021.112083_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40268-017-0197-5","article-title":"Eslicarbazepine acetate: a new improvement on a classic drug family for the treatment of partial-onset seizures","volume":"17","author":"Galiana","year":"2017","journal-title":"Drugs Rd."},{"key":"10.1016\/j.biopha.2021.112083_bib10","first-page":"215","article-title":"Membrane transporters in drug development","volume":"9","author":"International Transporter Consortium","year":"2010"},{"key":"10.1016\/j.biopha.2021.112083_bib11","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2174\/1381612043384844","article-title":"ABC transporters and the blood-brain barrier","volume":"10","author":"Begley","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2021.112083_bib12","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1528-1167.2011.03140.x","article-title":"In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein","volume":"52","author":"Zhang","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.biopha.2021.112083_bib13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bcpt.13031","article-title":"Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants","volume":"123","author":"Saiz-Rodr\u00edguez","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2021.112083_bib14","first-page":"1","article-title":"Avoiding complacency when treating uncontrolled seizures: why and how?","author":"Amin","year":"2020","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.biopha.2021.112083_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neulet.2017.01.014","article-title":"Pharmacogenomics in epilepsy","volume":"667","author":"Balestrini","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.biopha.2021.112083_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt1977213247","article-title":"Toward the operational identification of adverse drug reactions","volume":"21","author":"Karch","year":"1977","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2021.112083_bib17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.medcli.2016.06.012","article-title":"Evaluaci\u00f3n de la causalidad en las comunicaciones de reacciones adversas a medicamentos. algoritmo del sistema espa\u00f1ol de farmacovigilancia","volume":"147","author":"G\u00f3mez","year":"2016","journal-title":"Med. Cl\u00ednica."},{"key":"10.1016\/j.biopha.2021.112083_bib18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bcpt.12938","article-title":"Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers","volume":"122","author":"Saiz-Rodr\u00edguez","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2021.112083_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106574","article-title":"Effectiveness of eslicarbazepine acetate in dependency of baseline anticonvulsant therapy: Results from a German prospective multicenter clinical practice study","volume":"101","author":"Weissinger","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.biopha.2021.112083_bib20","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/epi.12242","article-title":"Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers","volume":"54","author":"Elger","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.biopha.2021.112083_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/CE.S142858","article-title":"Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy","volume":"13","author":"Lattanzi","year":"2018","journal-title":"Core Evid."},{"key":"10.1016\/j.biopha.2021.112083_bib22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.yebeh.2017.04.019","article-title":"Study 301, 302 and 304 investigators, adjunctive eslicarbazepine acetate: a pooled analysis of three phase III trials","volume":"72","author":"Biton","year":"2017","journal-title":"Epilepsy Behav. Eb."},{"key":"10.1016\/j.biopha.2021.112083_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cotox.2018.12.004","article-title":"Variability in expression of the human MDR1 drug efflux transporter and genetic variation of the ABCB1 gene: implications for drug-resistant epilepsy","volume":"11\u201312","author":"Heinrich","year":"2018","journal-title":"Curr. Opin. Toxicol."},{"key":"10.1016\/j.biopha.2021.112083_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1343650","article-title":"ABCB1 polymorphisms and drug-resistant epilepsy in a tunisian population","volume":"2019","author":"Chouchi","year":"2019","journal-title":"Dis. Markers"},{"key":"10.1016\/j.biopha.2021.112083_bib25","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eplepsyres.2014.03.019","article-title":"The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs","volume":"108","author":"Li","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.biopha.2021.112083_bib26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00439-020-02150-6","article-title":"Ethnogeographic and inter-individual variability of human ABC transporters","volume":"139","author":"Xiao","year":"2020","journal-title":"Hum. Genet."},{"key":"10.1016\/j.biopha.2021.112083_bib27","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1124\/dmd.111.038620","article-title":"Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation","volume":"39","author":"Loureiro","year":"2011","journal-title":"Drug Metab. Dispos."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221008660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221008660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:42:33Z","timestamp":1760100153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221008660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":27,"alternative-id":["S0753332221008660"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112083","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ABCB1 C3435T, G2677T\/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112083"}}